10-Q · May 7, 2026
Rocket Pharmaceuticals reported a significant decrease in operating expenses for Q1 2026, with R&D expenses down by $4.5 million to $31.5 million compared to Q1 2025. The net loss narrowed to $47.6 million from $61.3…
Earnings analysis · 10-Q
RCKT earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include income-statement, segment, balance-sheet working-capital, or cash-flow statement data, so revenue, margins, EPS, operating cash flow, and free cash flow trends cannot be assessed.…
Read full summary
The supplied 10-Q text does not include income-statement, segment, balance-sheet working-capital, or cash-flow statement data, so revenue, margins, EPS, operating cash flow, and free cash flow trends cannot be assessed. Liquidity improved, with cash, cash equivalents and investments rising to $283.7 million from $188.9 million at year-end 2025. The principal negative is ongoing securities and derivative litigation, while management reported effective disclosure controls and no material internal-control changes. No quantitative financial guidance was provided.
What stood out
-
Liquidity increased materially
Cash, cash equivalents and investments increased to $283.7 million at June 30, 2026 from $188.9 million at December 31, 2025, a $94.8 million increase.
-
Limited disclosed interest-rate sensitivity
The company’s investments are primarily in U.S. Treasury securities, and a 100-basis-point immediate increase in interest rates would have produced a hypothetical $0.1 million decline in net fair value.
-
Disclosure controls deemed effective
Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.
-
No material control changes
The company reported no changes in internal control over financial reporting during the period that materially affected, or were reasonably likely to materially affect, those controls.
What to watch
-
Consolidated securities litigation
Two securities class actions filed on June 11, 2025 and July 18, 2025 were consolidated; the amended complaint covers investors who acquired securities from February 28, 2024 through August 25, 2025. The company cannot predict the outcome or estimate a potential loss.
-
Derivative action and legal costs
A putative derivative action filed on October 22, 2025 remains stayed pending resolution of motions to dismiss the securities litigation; the company will pay legal fees related to the action and cannot estimate potential loss.
-
Unhedged investment-rate exposure
The company has $283.7 million of cash, cash equivalents and investments exposed to interest-rate changes, does not use interest-rate hedges, and estimates a $0.1 million fair-value decline from a 100-basis-point rate increase.
Management's outlook
No quantitative financial guidance or outlook was provided in the supplied 10-Q text. The filing states that material risk factors were disclosed in the 2025 Form 10-K and that there had been no material changes.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.